Invicro clinical scientists have unsurpassed experience and depth-of-knowledge in imaging neurologic disorders. For over 15 years, our clinical team has led the way in performing clinical imaging studies and trials in Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, Post-Traumatic Stress Disorder, Traumatic Brain Injury, Huntington’s Disease, Downs Syndrome, and other neuropsychiatric disorders.
Invicro’s breadth of experience in clinical neuroscience trials using quantitative biomarkers includes:
- Design and implementation of standardized quantitative dopamine transporter imaging studies for single-site, central site, and multi-site trials related to Parkinsonism.
- Design and implementation of centralized quantitative amyloid imaging studies and utilization of validated elgibility and longitudinal monitoring methods in Alzheimer disease (AD) and mild cognitive impairment (MCI) trials.
- Seamless integration of individualized MRI imaging with PET or SPECT studies, including region-specific analysis of grey matter/white matter and brain region segmentation.
- Proprietary methods for objective quantification of histopathological tissues and correlation with molecular imaging.
- Routine development and validation of quantitative outcome measures for novel first-in-human brain radiotracers.
- Extensive experience in the radiochemistry production, distribution, implementation, and state-of-the-art image analysis of tau radiotracers in clinical trials.
- Unparalleled experience in the novel application of imaging biomarkers for optimizing study enrollment and for the evaluation of disease-modifying treatment effects on progression across a wide range of CNS diseases.
Key Invicro scientists Kenneth Marek, John Seibyl, Roger Gunn and Ilan Rabiner (see here for more information) are thought-leaders in the fields of clinical neuroscience and quantitative imaging biomarkers with over 100 years of combined experience, more than 350 publications, and having held over 20 NIH grants.
Contact us for more information.